ERBB2 and breast cancer: Additionally, there were no significant differences in the administration of radiotherapy, anti-HER2 therapy, and endocrine therapy for primary breast cancer between the two groups (60.4% vs 64.4%, 18.9% vs 11.9%, and 34.0% vs 34.7%, p = 0.63, 0.24, and 0.93, respectively).